StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM
Oppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358
November 11, 2019 5:39 AM
Nektar Therapeutics (NKTR) PT Lowered to $40 at Cowen
November 7, 2019 8:26 AM
Nektar Therapeutics (NKTR) PT Lowered to $35 at Piper Jaffray
November 7, 2019 6:57 AM
Form 10-Q NEKTAR THERAPEUTICS For: Sep 30
November 7, 2019 6:05 AM
Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c
November 6, 2019 4:40 PM